HEARTLAND FHIR candidate 0.3.0 — draft, experimental R4 4.0.1 reference. Prepared for technical review; not evidence of clinical validation or vendor interoperability.

• Narrative Content
• XML
• JSON
• TTL

: HEARTLAND Evidence Level

Draft as of 2026-09-29

Raw xml | Download

<CodeSystem xmlns="http://hl7.org/fhir">
  <id value="heartland-evidence-level"/>
  <language value="en"/>
  <text>
    <status value="generated"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: CodeSystem heartland-evidence-level</b></p><a name="heartland-evidence-level"> </a><a name="hcheartland-evidence-level"> </a><p>This case-sensitive code system <code>https://fhir.heartlandprotocol.org/CodeSystem/heartland-evidence-level</code> defines the following codes:</p><table class="codes"><tr><td style="white-space:nowrap"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td style="white-space:nowrap">established<a name="heartland-evidence-level-established"> </a></td><td>Established Evidence</td><td>Interventions with strong guideline support, such as SGLT2i for all HF phenotypes endorsed by the 2022 AHA/ACC/HFSA guideline.</td></tr><tr><td style="white-space:nowrap">emerging<a name="heartland-evidence-level-emerging"> </a></td><td>Emerging Evidence</td><td>Recent trial findings not yet fully incorporated into guidelines, such as finerenone for HFpEF based on the FINEARTS-HF trial.</td></tr><tr><td style="white-space:nowrap">pragmatic<a name="heartland-evidence-level-pragmatic"> </a></td><td>Pragmatic Heuristic</td><td>Tools developed for clinical utility without formal statistical validation, such as the HEARTLAND Risk Score itself.</td></tr></table></div>
  </text>
  <url
       value="https://fhir.heartlandprotocol.org/CodeSystem/heartland-evidence-level"/>
  <version value="0.3.0"/>
  <name value="HeartlandEvidenceLevel"/>
  <title value="HEARTLAND Evidence Level"/>
  <status value="draft"/>
  <experimental value="true"/>
  <date value="2026-09-29T19:00:36-04:00"/>
  <publisher value="Vicky Muller Ferreira, MD"/>
  <contact>
    <name value="Vicky Muller Ferreira, MD"/>
    <telecom>
      <system value="url"/>
      <value value="https://heartlandprotocol.org"/>
    </telecom>
    <telecom>
      <system value="email"/>
      <value value="vickymuller@heartlandprotocol.org"/>
    </telecom>
  </contact>
  <contact>
    <name value="Vicky Muller Ferreira, MD"/>
    <telecom>
      <system value="email"/>
      <value value="vickymuller@heartlandprotocol.org"/>
      <use value="work"/>
    </telecom>
    <telecom>
      <system value="url"/>
      <value value="https://heartlandprotocol.org"/>
    </telecom>
  </contact>
  <description
               value="Three-tiered transparency labels distinguishing evidence strength behind HEARTLAND Protocol v3.2 recommendations, helping clinicians calibrate clinical decisions."/>
  <jurisdiction>
    <coding>
      <system value="urn:iso:std:iso:3166"/>
      <code value="US"/>
    </coding>
  </jurisdiction>
  <copyright value="CC-BY 4.0"/>
  <caseSensitive value="true"/>
  <content value="complete"/>
  <count value="3"/>
  <concept>
    <code value="established"/>
    <display value="Established Evidence"/>
    <definition
                value="Interventions with strong guideline support, such as SGLT2i for all HF phenotypes endorsed by the 2022 AHA/ACC/HFSA guideline."/>
  </concept>
  <concept>
    <code value="emerging"/>
    <display value="Emerging Evidence"/>
    <definition
                value="Recent trial findings not yet fully incorporated into guidelines, such as finerenone for HFpEF based on the FINEARTS-HF trial."/>
  </concept>
  <concept>
    <code value="pragmatic"/>
    <display value="Pragmatic Heuristic"/>
    <definition
                value="Tools developed for clinical utility without formal statistical validation, such as the HEARTLAND Risk Score itself."/>
  </concept>
</CodeSystem>